• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·ATLN
Share

Atlantic International Corp. Stocks

$ 0.6Last Updated 12.06.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 47.61M

$ 0.6
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

29.12.2025 19:30

Barron's advised avoiding Lucid shares and 21 other companies in 2026. What's wrong with that?

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Based in Billerica, Massachusetts, and established in 2013, Atlantic International Corp. (which operated as SeqLL Inc. until its name change in June 2024) underwent a significant corporate change on June 18, 2024, when it was acquired by Lyneer Investments, LLC, via a reverse merger. The company operates within the life sciences sector, providing specialized instrumentation and research services. Its primary focus is on generating innovative scientific assets and proprietary intellectual property across various "omics" disciplines. Central to its offerings is the True Single Molecule Sequencing (tSMS) platform. This advanced technology provides a unique single-molecule approach to DNA and RNA sequencing by directly detecting nucleic acids. It empowers researchers to analyze billions of individual molecules within a single experiment, ensuring the generation of highly accurate and reproducible data. Atlantic International's sophisticated solutions cater to diverse applications, including biomarker discovery and the development of diagnostic assays. Its clientele spans academic institutions (such as universities), governmental research centers, and leading companies in the biotechnology and pharmaceutical industries. The company also fosters key collaborations, including an R&D agreement with the U.S. Department of Justice's Federal Bureau of Investigation to assess the forensic potential of direct RNA sequencing using its tSMS platform, and a partnership with the Weizmann Institute of Science to advance and implement cutting-edge single-molecule technologies.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.06.2026 18:01

ECB has raised rates, next move is for the Fed: what will be Kevin Warsh's first decision

14.06.2026 15:01

"A premium for candor": how top executives' comments affect companies' share prices

13.06.2026 22:31

U.S. and Iran to sign agreement on June 14, Strait of Hormuz to reopen - Trump

13.06.2026 16:01

Small caps last week: Record biotech IPO, Wizz Air's solid top line, SpaceX effect

13.06.2026 13:01

An investment idea for all times, IPO of the year and how to keep emotions in check in the stock market

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026